



21st World Congress in Fetal Medicine



Lisbon 2024

DIAMOND SPONSOR



GE HealthCare

Get through your day up to
25% faster



Scan for more
information

Meet the new Voluson™ Signature series at our booth

Explore our systems with a phantom live scan at our booth.

© 2024 GE HealthCare. Voluson is a trademark of GE HealthCare. GE is a trademark of General Electric Company used under trademark license. JB28488XX. Commercial availability of GE HealthCare medical systems is subject to meeting local requirements in a given country or region. Contact a GE HealthCare Representative for more information. Intended for healthcare professionals only.

21st World Congress in Fetal Medicine

Sunday 23rd June 2024: Joint session with Eurofoetus

- 09:05 - 11:10 Fetal spina bifida repair
- 11:45 - 13:00 Special lectures
- 14:00 - 15:30 Controversies in fetal surgery
- 15:30 - 17:00 Special lectures
- 17:00 - 18:50 Congenital diaphragmatic hernia
- 20:30 - 23:00 Welcome reception

Monday 24th June 2024: Joint session with Eurofoetus

- 08:00 - 08:45 GE Healthcare live scan session
- 09:00 - 13:10 Monochorionic twin complications
- 14:30 - 15:20 Fetal shunts
- 15:20 - 16:00 Special lectures
- 16:30 - 19:00 Neurosonography

Tuesday 25th June 2024

- 08:00 - 08:45 Samsung live scan session
- 09:00 - 12:40 Fetal growth restriction
- 12:40 - 13:10 Special lectures
- 14:20 - 16:02 Preterm birth
- 16:02 - 16:15 Special lecture
- 17:00 - 19:10 Fetal cardiology
- 21:00 - 02:00 Dinner party

Wednesday 26th June 2024

- 09:00 - 11:10 Fetal ultrasound meets genetics
- 11:40 - 13:00 Topics in maternal – fetal medicine
- 14:00 - 15:00 Maternal hemodynamics
- 15:00 - 19:10 Preeclampsia

Thursday 27th June 2024

- 09:00 - 10:20 Labor and delivery
- 10:20 - 11:00 Congenital infections
- 11:30 - 12:15 Special lectures
- 12:15 - 13:15 The 36 weeks scan
- 16:00 - 22:30 Trip to Cascais

DIAMOND SPONSOR



GE HealthCare

Join our morning session

Meet the Experts for a Live Scan

with Prof. Ritsuko Pooh
& Prof. Rabih Chaoui

Monday, June 24th
08:00 – 08:45h | Main Lecture Hall

Topic: Latest technologies in
2D/3D fetal imaging of brain
and heart.



Voluson™
A Healthier Future for Women

© 2024 GE HealthCare. Voluson is a trademark of GE HealthCare. GE is a trademark of General Electric Company used under trademark license. JB28488XX. Commercial availability of GE HealthCare medical systems is subject to meeting local requirements in a given country or region. Contact a GE HealthCare Representative for more information. Intended for healthcare professionals only.

Sunday 23rd June 2024: Joint session with Eurofoetus

08:00 - 09:00 Registration

09:00 - 09:05 Welcome Kypros Nicolaides (UK)

09:05 - 11:10 Fetal spina bifida repair Discussants: Jan Deprest (Belgium), Greg Ryan (Canada)

09:05 - 09:15	MOMS cohorts: outcomes and their prenatal predictors	Diana Farmer (USA)
09:15 - 09:25	The NAFTNET registry	Anthony Johnson (USA)
09:25 - 09:35	Mini-laparotomy assisted repair	Ramen Chmait (USA)
09:35 - 09:45	Risk factors for prematurity and uterine dehiscence	Jan Deprest (Belgium)
09:45 - 09:55	Discussion	
09:55 - 10:10	Selection of candidates for repair based on US and MRI	Magdalena Sanz-Cortes (USA)
10:10 - 10:20	Parental decisions following assessment in fetal surgery	Emma van den Eede (Belgium)
10:20 - 10:30	Biocellulose based repair	Denise Lapa (Brazil)
10:30 - 10:40	Use of stem cell seeded patches	Diana Farmer (USA)
10:40 - 10:50	Outcome of fetal limited dorsal myeloschisis (LDM)	Jean-Marie Jouannic (France)
10:50 - 11:00	MRI prediction of ambulation, bladder function, sensorial level	Romain Corroenne (USA)
11:00 - 11:10	Neurosurgical outcomes of fetoscopic repair of open spina bifida	Nerea Maiz (Spain)

11:10 - 11:45 Coffee break

11:45 - 13:00 Special lectures Discussants: Jan Deprest (Belgium), Alexandra Benachi (France)

11:45 - 12:00	In utero enzyme, gene and cell therapy	Tippi MacKenzie (USA)
12:00 - 12:15	In utero gene therapy for hemophilia	Graca Almeida-Porada (USA)
12:15 - 12:30	In utero gene therapy for sickle cell disease	Panicos Shangaris (UK)
12:30 - 12:45	Fetal medical treatment for Down Syndrome	Diana Bianchi (USA)
12:45 - 13:00	The mortality of politics	Mark Evans (USA)

13:00 - 14:00 Lunch break

14:00 - 15:30 Controversies in fetal surgery Discussants: Yves Ville (France), Anthony Johnson (USA)

14:00 - 14:15	Brain and spine	
14:00 - 14:10	Third ventriculostomy for hydrocephalus	Fabio Peralta (Brazil)
14:10 - 14:20	Systematic review of surgical interventions for fetal hydrocephalus	Anthony Hart (UK)
14:20 - 14:30	Surgery for encephalocele	Sergio Cavalheiro (Brazil)
14:30 - 14:45	Discussion	William Whitehead (USA)
14:45 - 15:30	Gastroschisis and exomphalos	
14:45 - 14:55	Experimental evidence of bowel rescue in the fetal lamb	Tomohiro Arai (Japan & Belgium)
14:55 - 15:05	Clinical experience with fetal surgery	Michael Belfort (USA)
15:05 - 15:15	Fetal botulinum toxin injection for giant omphalocele	Miguel Parra Saavedra (Colombia)
15:15 - 15:30	Discussion	

15:30 - 17:00 Special lectures Managing critically ill pregnant patients Fetal intervention for HLHS with restrictive atrial septum

Amir Shamshirsaz (USA)
Shaine Morriss (USA)

16:00 - 16:30 Coffee break

16:30 - 16:45	Fetal organoids - prediction model for pulmonary hypoplasia	Paolo De Coppi (UK)
16:45 - 16:55	Kidney and lung organoids from cells in amniotic fluid	Oren Pleniceanu (Israel)
16:55 - 17:00	Discussion	

17:00 - 18:50 Congenital diaphragmatic hernia Discussants: Alexandra Benachi (France), Jan Deprest (Belgium)


17:00 - 17:10	Fetal treatment - overview	Jan Deprest (Belgium)
17:10 - 17:20	Whole exome sequencing for CDH	Philip DeKonick (Netherlands)
17:20 - 17:32	Prediction of PRROM in FETO for CDH	Alexandra Benachi (France)
17:32 - 17:44	Fetal lung MRI and lung function	Lisa Story (UK)
17:44 - 17:56	Long term neurocognitive outcome	Enrico Danzer (USA)
17:56 - 18:08	Fetal heart in CDH	Daniela Laux (France)
18:08 - 18:20	Relationship of neonatal management with early morbidity	Dick Tibboel (Netherlands)
18:20 - 18:32	An update on smart tracheal occlusion	Francesca Russo (Belgium)
18:32 - 18:50	Discussion	

20:30 - 23:00 Welcome reception

DIAMOND SPONSOR

Life-long Healthcare Solutions
for Women

SAMSUNG



Samsung is committed to creating a healthier future for medical professionals and patients as well as to supporting life-long healthcare for women by pursuing innovative healthcare solutions.

Samsung will continuously focus on innovating AI technologies to enhance more diagnostic confidence and healthier future.



Visit Website

Morning Live Scan Session

Tuesday, 25 June 08:00am – 08:45am Plenary Room

Advanced Ultrasound Technologies in Prediction and Management of Placental Insufficiency: Fetal Growth Restriction and Preeclampsia.

Prof. Basky Thilaganathan(UK)

Monday 24th June 2024: Joint session with Eurofoetus

08:00 - 08:45 **GE Healthcare live scan session:** Latest technologies in 2D / 3D fetal imaging of brain and heart

Ritsuko Pooh (Japan)
Rabih Chaoui (Germany)

09:00 - 13:10 **Monochorionic twin complications**
Discussants: Yves Ville (France), Liesbeth Lewi (Belgium)

09:00 - 09:10 TTTS and TAPS
09:10 - 09:20 TTTS in triplets and quadruplets
09:20 - 09:30 TTTSor not?
09:30 - 09:40 What to look for after fetoscopic laser surgery for TTTS
09:40 - 09:50 RCT: selective vs. sequential laser separation in TTTS
09:50 - 10:00 Laparotomy-assisted fetoscopic laser surgery for TTTS and TAPS
10:00 - 10:10 The hepatic arterial buffer response in TTTS
10:10 - 10:20 Diagnosis and outcome of spontaneous TAPS
10:20 - 10:45 Discussion
10:45 - 11:00 Simulation training for fetoscopic laser surgery in TTTS

Yves Ville (France)
Kurt Hecher (Germany)
Greg Ryan (Canada)
Anthony Johnson (USA)
Ramen Chmait (USA)
Jose Peiro (USA)
Jader Cruz (Portugal)
Eva Bosmans (Belgium)

Rogelio Cruz-Martinez (Mexico)

11:00 - 11:30 **Coffee break**

11:30 - 11:40 Rarities in MC twin pregnancies
11:40 - 11:50 Severe sFGR: selective reduction
11:50 - 12:00 Umbilical cord insertions in sFGR
12:00 - 12:10 Discussion
12:10 - 12:20 Microwave ablation for selective reduction in complicated MC twins
12:20 - 12:40 Brain anomalies in complicated MC twins

12:40 - 12:50 Management of monoamniotic twins
12:50 - 13:00 Fetoscopic ablation therapy for vasa previa types II and III
13:00 - 13:10 Discussion

Liesbeth Lewi (Belgium)
Anne Noll (Sweden)
Enrico Lopriore (Netherlands)

Mara Rosner (USA)
Yoav Yinon (Israel)
Shiri Shinar (Canada)
Lennart Van der Veken (Canada)
Ramen Chmait (USA)

13:10 - 14:30 **Lunch break**

14:30 - 15:20 **Fetal shunts**
Discussants: Greg Ryan (Canada), Katia Bilardo (Netherlands), Kypros Nicolaides (UK)

14:30 - 14:40 Global registry on complications after shunting for hydrothorax
14:40 - 14:50 Natural history of megacystis
14:50 - 15:00 The Somatex shunt
15:00 - 15:10 Causes of megacystis in 1st trimester shunted fetuses
15:10 - 15:20 Novel shunt with valve

Monique Haak (Netherlands)
Federica Fontanella (Netherlands)
Christoph Berg (Germany)
Eva Christin Weber (Germany)
Enrico Danzer (USA)

15:20 - 16:00 **Special lectures**
15:20 - 15:30 Fetal resuscitation during cardiac procedures
15:30 - 15:40 Nipocalimab in red cell isoimmunization: phase III study
15:40 - 15:50 Sirolimus for fetal lymphatic malformations
15:50 - 16:00 Artificial placenta: brain oxygenation and hemodynamic status

Shaine Morriss (USA)
Mark Kilby (UK)
Magdalena Sanz-Cortes (USA)
Elisenda Eixarch (Spain)

16:00 - 16:30 **Coffee break**

16:30 - 19:00 **Neurosonography**
Discussants: Magdalena Sanz-Cortes (USA), Dario Paladini (Italy)

16:30 - 16:45 Genetic basis of fetal brain abnormalities
16:45 - 17:00 Coronal view of the brain in the 2nd and 3rd trimester
17:00 - 17:15 Fetal CNS: lessons from daily practice
17:15 - 17:30 The syndromic brain
17:30 - 17:45 Mystery of molar tooth sign in Joubert's syndrome
17:45 - 18:00 RASopathies revisited
18:00 - 18:10 Subarachnoid space in macro- and microcephaly
18:10 - 18:20 'Seagull sign' and thinned subplate in Down syndrome
18:20 - 18:30 Cortical brain morphometry in adults born-FGR
18:30 - 19:00 Discussion

Tessa Homfray (UK)
Rabih Chaoui (Germany)
Guillermo Azumendi (Spain)
Dario Paladini (Italy)
Ritsuko Pooh (Japan)
Karina Haratz (Israel)
Eldad Katorza (Israel)
Wirada Dulyaphat (Thailand)
Elisenda Eixarch (Spain)

DIAMOND SPONSOR

BurjeelMedicalCity.com



Hope starts here.

Burjeel Medical City's Kypros Nicolaides Center leads in fetal medicine, specializing in diagnosing and treating fetal anomalies like spina bifida. Our expert team of fetal surgeons uses cutting-edge technology and evidence-based practices to ensure the best outcomes. We provide exceptional care and support for both mother and baby with a compassionate approach and state-of-the-art technology.

Contact Us Today to Learn More or Schedule a Consultation
Visit our website burjeelmedicalcity.com or call us at **+971 800 23**

**KYPROS
NICOLAIDES**

Fetal Medicine & Therapy Center
a burjeel holdings company

BMC BURJEEL
MEDICAL
CITY

Safeguarding your health
at the world's safest city



PlGF-based testing— a game changer in pre-eclampsia care.

We are Revvity. And we bring with us 35 years of knowledge, expertise, and innovation in maternal fetal health. We offer a portfolio of prenatal solutions, including our high-sensitivity DELFIA® Xpress PlGF 1-2-3™ kit. This assay can be performed in the first trimester and allows for early risk assessment of pregnancy complications such as pre-eclampsia.

A single kit for risk assessment, short-term prediction, and to aid in diagnosis

- DELFIA Xpress PlGF 1-2-3 kit can be performed in all trimesters
- 1T screening in combination with aspirin, results in 82% reduction in the incidence of early preterm pre-eclampsia.¹
- 2T/3T simple solution to help rule in and rule out suspected preterm pre-eclampsia

1. Daniel L. Rolnik et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. New England J Med 2017; 377:613-622
DOI: 10.1056/NEJMoa1704559

www.revvity.com

Products may not be licensed in accordance with the laws in all countries, such as the United States and Canada. Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details. Revvity does not endorse or make recommendations with respect to research, medication, or treatments. All information presented is for informational purposes only and is not intended as medical advice. For country specific recommendations, please consult your local health care professionals.

08:00 - 08:45 **Samsung live scan session:** Advanced ultrasound technologies in prediction and management of PE and FGR Basky Thialaganathan (UK)

09:00 - 12:40 **Fetal growth restriction**
Discussants: Christoph Lees (UK), Raffaele Napolitano (UK), Ioannis Papastefanou (Greece)

09:00 - 09:12	Genetic issues	Antoni Borrell (Spain)
09:12 - 09:24	Birth weight influences cardiac structure, function, and disease risk	Maddalena Ardisino (UK)
09:24 - 09:30	Discussion	
09:30 - 09:42	Individualized pathway of care	Ioannis Papastefanou (Greece)
09:42 - 09:54	Timing of delivery	Christoph Lees (UK)
09:54 - 10:00	Discussion	
10:00 - 10:10	RCT: Term delivery based on FGR +/- CPR (RATIO37)	Marta Rial Crestelo (Spain)
10:10 - 10:20	Angiogenic factors versus Doppler in term FGR and SGA	Manel Mendoza (Spain)
10:20 - 10:30	Angiogenic factors and increasing severity of FGR	Lina Youssef (Spain)
10:30 - 10:40	Cerebroplacental ratio at 36 weeks	Ranjit Akolekar (UK)
10:40 - 10:50	Late FGR: Ultrasound predictors of adverse neonatal outcomes	Raffaele Napolitano (UK)
10:50 - 11:00	Discussion	

11:00 - 11:30 Coffee break

11:30 - 12:00	Cases based discussion	Raffaele Napolitano (UK)
12:00 - 12:10	FGR: cardiac remodeling and exercise tolerance in adolescence	Rommy Novoa (Spain)
12:10 - 12:20	Growth trajectories in twins	Hamutal Meiri (Israel)
12:20 - 12:30	Use of the FMF chart for twins in the prediction of stillbirth	Steffen Kristensen (Denmark)
12:30 - 12:40	Discussion	

12:40 - 13:10 Special lectures

12:40 - 12:55	Non-reportable cfDNA results: what is the risk of maternal cancer?	Diana Bianchi (USA)
12:55 - 13:10	The need to reduce uncertainty in medicine	Ben Mol (Australia)

13:10 - 14:20 Lunch break

14:20 - 16:02 Preterm birth

Discussants: Kypros Nicolaides (UK), Steve Thornton (UK)

14:20 - 14:32	RCT: pessary vs cerclage to prevent recurrent preterm birth	Annabelle van Gils (Netherlands)
14:32 - 14:44	RCT: cerclage for short cervix in twins	Ben Mol (Australia)
14:44 - 14:56	RCT: pessary vs progesterone for short cervix in multiples	Charlotte van Dijk (Netherlands)
14:56 - 15:10	Discussion	
15:10 - 15:22	RCT: docosahexaenoic acid supplementation in pregnancy	Carl Weiner (USA)
15:22 - 15:32	PPROM managed according to amniotic fluid analysis	Teresa Cobo (Spain)
15:32 - 15:42	Placental multimodal MRI prior to preterm birth	Megan Hall (UK)
15:42 - 15:52	Machine learning to predict imminent birth	Gal Cohen (Israel)
15:52 - 16:02	QUIPP app for prediction of PTB in asymptomatic high-risk women	Lyndsay Creswell (Ireland)

16:02 - 16:15 **Special lecture:** Fetal growth, evolution and emancipation Gerry Visser (Netherlands)

16:15 - 17:00 Coffee break

17:00 - 19:10 Fetal cardiology

Discussants: Rabih Chaoui (Germany), Julene Carvalho (UK)


17:00 - 17:15	Genetic basis of fetal cardiac abnormalities	Tessa Homfray (UK)
17:15 - 17:25	CHD: incremental diagnostic yield with prenatal exome sequencing	Kelly Reilly (N Ireland)
17:25 - 17:45	Fetal echo: moving from the 2nd to the 1st Trimester	Rabih Chaoui (Germany)
17:45 - 17:55	Ebstein's anomaly and tricuspid valve dysplasia	Roland Axt-Fliedner (Germany)
17:55 - 18:25	Presentation of cases	Julene Carvalho (UK)
18:25 - 18:35	1st trimester color Doppler patterns in congenital heart defects	Valentina De Robertis (Italy)
18:35 - 18:45	Biventricular dysfunction in Tetralogy of Fallot	Fatima Crispi (Spain)
18:45 - 18:55	Nationwide study on prenatal detection and outcome of CHD	Cathrine Vedel (Denmark)
18:55 - 19:10	Discussion	

21:00 - 02:00 Dinner party




for Precise and Efficient Ultrasound Diagnosis

With the latest artificial intelligence integrated into our expert tools and technologies, we support healthcare professionals for accurate and faster diagnosis and better patient outcomes.




HeartAssist™

Automated reporting tool for fetal heart diagnosis



ViewAssist™

Automated classification of the images
and annotation of the structures



Biometry Assist™

Automated measurement of fetal biometry

GOLD SPONSOR



Transforming the future of health

An exclusive focus on healthcare empowers us to tackle the world's toughest health challenges. We innovate across the full spectrum of healthcare solutions today to uniquely position us for the breakthroughs of tomorrow.

Learn more at [jnj.com](https://www.jnj.com)

Johnson & Johnson

©JJSI2024

09:00 - 11:10 Fetal ultrasound meets genetics

Discussants: Oliver Kagan (Germany), Tessa Homfray (UK)

09:00 - 09:10	cfDNA test in dichorionic twin and vanishing twin pregnancies	Jacintha van Eekhout (Netherlands)
09:10 - 09:20	cfDNA test in triplet pregnancies	Alexandre Vivanti (France)
09:20 - 09:30	Uterine fibroids and cfDNA screening failure	Daniel Rolnik (Australia)
09:30 - 09:45	Presentation of cases	Oliver Kagan (Germany)
09:45 - 09:55	Genomic testing for genetic disease in structurally "normal" fetus & neonate	Mark Kilby (UK)
09:55 - 10:05	Robertsonian translocations	Peter Benn (USA)
10:05 - 10:15	Should patients carrying T21 fetuses be managed with Dopplers?	Angela Ranzini (USA)
10:15 - 10:25	Detection of fetal anomalies by 1st trimester scan in the Czech Republic	Pavel Calda (Czech Republic)
10:25 - 10:35	High NT and normal chromosomal microarray	Kasper Gadsbøll (Denmark)
10:35 - 10:45	Residual risks for chromosomal aberrations in patients with normal cfDNA test	Sophie Ottema (Netherlands)
10:45 - 10:55	Circulating extravillous trophoblasts sequencing for pCNV screening	Thomas Musci (USA)
10:55 - 11:10	Discussion	

11:10 - 11:40 Coffee break

11:40 - 13:00 Topics in maternal – fetal medicine

Discussants: Catherine Williamson (UK), Roland Devlieger (Belgium)

11:40 - 11:52	Obesity	Roland Devlieger (Belgium)
11:52 - 12:04	New bile acid therapies	Catherine Williamson (UK)
12:04 - 12:16	Hyperemesis gravidarum	Melanie Nana (UK)
12:16 - 12:26	Assessment of liver steatosis and fibrosis	Luiza Manna (UK)
12:26 - 12:36	Postnatal assessment of women with gestational diabetes	Mairead Hamill (UK)
12:36 - 12:48	Physical activity during pregnancy and perinatal mental health	Maia Brik (Spain)
12:48 - 13:00	Discussion	

13:00 - 14:00 Lunch break

14:00 - 15:00 Maternal hemodynamics

Discussants: Herbert Valensise (Italy), Marietta Charakida (UK), Basky Thialaganathan (UK)

14:00 - 14:15	The cardio-fetal-placental unit in fetal growth restriction	Herbert Valensise (Italy)
14:15 - 14:30	Maternal hemodynamics in PE and GDM	Marietta Charakida (UK)
14:30 - 14:40	Prediction of PE by maternal cardiovascular hemodynamics at 12-16 weeks	Lo Wong (Hong Kong)
14:40 - 14:50	Cerebral Doppler: signs of maternal and fetal vasoconstriction	Markus Gonser (Switzerland)
14:50 - 15:00	Discussion	

15:00 - 19:10 Preeclampsia

Discussants: Liona Poon (Hong Kong), Laura Magee (UK), Peter von Dadelszen (UK)

15:00 - 15:12	Genetic contribution to prediction of PE	Antonio de Marvao (UK)
15:12 - 15:24	Cell-free DNA methylome analysis for prediction of early PE	Lore Lannoo (Belgium)
15:24 - 15:36	RCT: beetroot in the prevention of PE	Nikos Kametas (UK)
15:36 - 15:48	RCT: Mediterranean diet in the prevention of PE	Francesca Crovetto (Spain)
15:48 - 16:00	Discussion	

16:00 - 16:30 Coffee break

16:30 - 16:42	RCT: optimal timing of birth in chronic or gestational hypertension at term	Laura Magee (UK)
16:42 - 16:54	Prediction of adverse outcomes by remote blood pressure monitoring	Stefan Verlohren (Germany)
16:54 - 17:06	How to improve maternal health following preeclampsia	Basky Thialaganathan (UK)
17:06 - 17:16	Maternal calcium intake and preeclampsia	Anastasija Arechvo (UK)
17:16 - 17:30	Discussion	
17:30 - 17:40	Implementation of first trimester screening and prevention in Asia	Liona Poon (Hong Kong)
17:40 - 17:50	Implementation of first trimester screening and prevention in Spain	Mar Gil (Spain)
17:50 - 18:00	Protocol for RCT on PE prevention in Denmark	Iben Riishede (Denmark)
18:00 - 18:12	Study design using discrete event simulation	David Wright (UK)
18:12 - 18:22	Postpartum hemorrhage in patients on ASA 162 mg/d for PE prevention	Ana Werlang (Canada)
18:22 - 18:32	Low fetal fraction of cfDNA testing and adverse pregnancy outcome	Ellis Becking (Netherlands)
18:32 - 18:42	Ophthalmic artery Doppler in twin pregnancies	Petya Chaveeva (Bulgaria)
18:42 - 18:52	Aspirin dose and development of PE in twin pregnancy	Pierpaolo Zorzato (Belgium)
18:52 - 19:10	Discussion	



Volutracer®
OPUS

OPTICAL POSITIONING ULTRASOUND SIMULATOR

SILVER SPONSOR

illumina®

Why should you prefer an IVDR certified NIPT test for your patients?

Hear why the European IVD-Regulations, applied to NIPT tests, matter for you as a referring clinician, and not only for the lab conducting the test. Webinar duration 20 min

Why IVDR Certification for NIPT Test Matter?

- Reliable test results
- Extensive clinical validation
- External review and assessment
- Streamlined post-market surveillance
- Locally performed tests



Watch now

Speaker: Jennifer Stobbs
Sr. Product Marketing Manager IVDR, Illumina

M-EMEA-01208

SILVER SPONSOR

ThermoFisher
SCIENTIFIC

Short-term prediction of pre-eclampsia

***sFlt-1/PIGF < 66**
Low risk

66

sFlt-1/PIGF ≥ 66
High risk

Women at low risk for progression to pre-eclampsia within one week may have an expectant management.¹

¹ Andersen et al., JAMA 2021

* Thermo Scientific™ B-R-A-H-M-S™ sFlt-1 KRYPTOR™ and Thermo Scientific™ B-R-A-H-M-S™ PIGF plus KRYPTOR™ assays

Women at high risk for progression to pre-eclampsia within one week need surveillance and may need hospitalization.¹

Learn more at thermoscientific.com/brahms

Visit our booth to get more information

Thermo Fisher Scientific products are distributed globally. Uses, applications, and availability of products in each country depend on local regulatory marketing authorization status. © 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. BMKT001384.1



SILVER SPONSOR

Tune out the noise with Harmony.

The Harmony test is the most proven cell-free DNA-based prenatal blood screen.¹ Designed to deliver focused results, it keeps false positive rates low so you and your patient can focus on what truly matters.

**Without Harmony,
it's just noise.**

harmonytest.roche.com

1. Demonstrated by 67 peer-reviewed published studies using the Harmony prenatal test as of Jan 2020. For the entire 67 references, please go to harmonytest.roche.com/references. The Harmony Prenatal Test is a non-invasive prenatal test (NIPT) based on cell-free DNA analysis. Harmony does not screen for potential chromosomal or genetic conditions other than those expressly identified here. The results are intended for prenatal screening and are not intended to be the sole basis for diagnosis. Harmony test results are intended to be used in conjunction with other clinical and diagnostic findings, consistent with professional standards of practice, including confirmatory fetal diagnostic testing, parental evaluation, clinical genetic evaluation, and counseling, as appropriate. This test is offered as a CE-IVD. *This test has not been cleared or approved by the US FDA. *Note: Because the fetal sex determination test option does not have a medical purpose, it does not meet the definition of an IVD device and therefore is not a CE-marked product. HARMONY and DANSR are trademarks of Roche. All other product names and trademarks are the property of their respective owners. © 2024 F. Hoffmann–La Roche, Ltd. MC-14329 03/2024

harmony[®]

Roche

SILVER SPONSOR

PHILIPS

WCFM 2024

We are excited to meet you at WCFM 2024, where we'll showcase our latest innovations in OB/GYN ultrasound specifically designed to not only aid in efficient routine screening and care, but also to aid clinicians in detecting abnormalities.

Have you already heard of Philips FetView? By scanning below QR code you can book your free trial now.



We look forward welcoming you at our booth #C2 in the FIL - Lisbon Exhibition and Congress Centre.



www.philips.com/obgyn

09:00 - 10:20 Labor and delivery
Discussants: Emmanuel Bujold (Canada), Tullio Ghi (Italy)

09:00 - 09:10	Lower uterine segment thickness to predict uterine rupture	Emmanuel Bujold (Canada)
09:10 - 09:20	MRI for reduction of macrosomia-related birth complications	Dominique Badr (Belgium)
09:20 - 09:30	Fetal cardiac function in early labor	Andrea Dall'Asta (Italy)
09:30 - 09:40	Cervical length prior to spontaneous labor at term	Piya Chaemsaitong (Thailand)
09:40 - 09:50	Placental abruption	Offer Erez (Israel)
09:50 - 10:05	Role of the pelvic floor in vaginal delivery	Aly Youssef (Italy)
10:05 - 10:20	Ultrasound to improve safety of difficult operative vaginal delivery	Tullio Ghi (Italy)

10:20 - 11:00 Congenital infections
Discussant: Yves Ville (France)

10:20 - 10:40	Update on congenital infections	Yves Ville (France)
10:40 - 10:50	cfDNA testing of maternal blood for CMV	Nicolas Bourgon (France)
10:50 - 11:00	Effects of maternal syphilis on the fetus	Edgar Hernandez Andrade (USA)

11:00 - 11:30 Coffee break

11:30 - 12:15 Special lectures

11:30 - 11:45	Saving money costs too much	Mark Evans (USA)
11:45 - 12:05	Communication in Fetal Medicine	Elena Greco (UK)
		Ioannis Karapanos (UK)
		Jane Fisher (UK)
		Surabhi Nanda (UK)
12:05 - 12:15	Palliative care in Fetal Medicine	

12:15 - 13:15 The 36 weeks scan
Discussant: Kypros Nicolaides (UK)

12:15 - 12:25	Diagnosis of fetal abnormalities	Argyro Syngelaki (UK)
12:25 - 12:35	Diagnosis and outcome of abnormal presentation	Marina Fitiri (UK)
12:35 - 12:45	Assessment of fetal growth	Stephen Adjahou (UK)
12:45 - 12:55	sFlt-1/PIGF: prediction of intrapartum fetal compromise	Paolo Cavoretto (Italy)
12:55 - 13:05	Maternal vascular – placental axis in GDM, PE and GH	Christos Chatzakis (Greece)
13:05 - 13:15	Prediction and prevention of term PE	Kypros Nicolaides (UK)

13:15 - 14:30 Lunch break

16:00 - 22:30 Trip to Cascais



SILVER SPONSOR

Exceptional 22q screening

Identifies 22q deletions of all sizes with 83% sensitivity.

Visit is the Natera booth to learn more!



Panorama™
Next-generation NIPT

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com

Panorama™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2024 Natera, Inc. All Rights Reserved.

22q



SILVER SPONSOR



AI-powered* Prenatal Ultrasound Reporting Solution

Sonio is a highly customizable reporting solution powered by AI for automation, efficiency, and quality control. The innovative cloud-based, AI-powered solution, is designed to simplify and streamline ultrasound workflows while ensuring quality assurance and clinical outcomes for patients.

Based on over five years of research and collaboration with leading fetal medicine and AI experts. Our mission is to improve global access and quality of care for women and children through artificial and collective intelligence.

*Clinical AI capabilities are part of FDA 510(k) cleared Sonio Detect. The Sonio platform includes both, Sonio Pro and Sonio Detect.



Learn more
about Sonio





Advances in Fetal Medicine Course 7 - 8 December 2024, London

Registration will open in July 2024
Limited number of places

Registration fee is £150, which includes lunches and coffees

Speaker List:

Alexandra Benachi (France)	Gal Cohen (Israel)	Miguel Parra Saavedra (Colombia)
Alexandre Vivanti (France)	Gerry Visser (Netherlands)	Monique Haak (Netherlands)
Aly Youssef (Italy)	Graca Almeida-Porada (USA)	Nerea Maiz (Spain)
Amir Shamshirsaz (USA)	Greg Ryan (Canada)	Nicolas Bourgon (France)
Ana Werlang (Canada)	Guillermo Azumendi (Spain)	Nikos Kametas (UK)
Anastasija Arehvo (UK)	Hamutal Meiri (Israel)	Offer Erez (Israel)
Andrea Dall'Asta (Italy)	Herbert Valensise (Italy)	Oliver Kagan (Germany)
Angela Ranzini (USA)	Iben Riishede (Denmark)	Oren Pleniceanu (Israel)
Annabelle van Gils (Netherlands)	Ioannis Karapanos (UK)	Panicos Shangaris (UK)
Anne Noll (Sweden)	Ioannis Papastefanou (Greece)	Paolo Cavoretto (Italy)
Anthony Hart (UK)	Jacintha van Eekhout (Netherlands)	Paolo De Coppi (UK)
Anthony Johnson (USA)	Jader Cruz (Portugal)	Pavel Calda (Czech Republic)
Antoni Borrell (Spain)	Jan Deprest (Belgium)	Peter Benn (USA)
Antonio de Marvao (UK)	Jane Fisher (UK)	Peter von Dadelszen (UK)
Argyro Syngelaki (UK)	Jean-Marie Jouannic (France)	Petya Chaveeva (Bulgaria)
Basky Thilaganathan (UK)	Jose Peiro (USA)	Philip DeKonick (Netherlands)
Ben Mol (Australia)	Julene Carvalho (UK)	Pierpaolo Zorzato (Belgium)
Carl Weiner (USA)	Karina Haratz (Israel)	Piya Chaemsaithong (Thailand)
Catherine Williamson (UK)	Kasper Gadsbøll (Denmark)	Rabih Chaoui (Germany)
Cathrine Vedel (Denmark)	Katia Bilardo (Netherlands)	Raffaele Napolitano (UK)
Charlotte van Dijk (Netherlands)	Kelly Reilly (N Ireland)	Ramen Chmait (USA)
Christoph Berg (Germany)	Kurt Hecher (Germany)	Ranjit Akolekar (UK)
Christoph Lees (UK)	Kyros Nicolaides (UK)	Ritsuko Pooh (Japan)
Christos Chatzakis (Greece)	Laura Magee (UK)	Rogelio Cruz-Martinez (Mexico)
Daniel Rolnik (Australia)	Lennart Van der Veken (Canada)	Roland Axt-Fliedner (Germany)
Daniela Laux (France)	Liesbeth Lewi (Belgium)	Roland Devlieger (Belgium)
Dario Paladini (Italy)	Lina Youssef (Spain)	Romain Corroenne (USA)
David Wright (UK)	Liona Poon (Hong Kong)	Rommy Novoa (Spain)
Denise Lapa (Brazil)	Lisa Story (UK)	Sergio Cavalheiro (Brazil)
Diana Bianchi (USA)	Lo Wong (Hong Kong)	Shaine Morris (USA)
Diana Farmer (USA)	Lore Lannoo (Belgium)	Shiri Shinar (Canada)
Dick Tibboel (Netherlands)	Luiza Manna (UK)	Sophie Ottema (Netherlands)
Dominique Badr (Belgium)	Lyndsay Creswell (Ireland)	Stefan Verlohren (Germany)
Edgar Hernandez Andrade (USA)	Maddalena Ardissino (UK)	Steffen Kristensen (Denmark)
Eldad Katorza (Israel)	Magdalena Sanz-Cortes (USA)	Stephen Adjahou (UK)
Elena Greco (UK)	Maia Brik (Spain)	Steve Thornton (UK)
Elisenda Eixarch (Spain)	Mairead Hamill (UK)	Surabhi Nanda (UK)
Ellis Becking (Netherlands)	Manel Mendoza (Spain)	Teresa Cobo (Spain)
Emma van den Eede (Belgium)	Mar Gil (Spain)	Tessa Homfray (UK)
Emmanuel Bujold (Canada)	Mara Rosner (USA)	Thomas Musci (USA)
Enrico Danzer (USA)	Marietta Charakida (UK)	Tippi MacKenzie (USA)
Enrico Lopriore (Netherlands)	Marina Fitiri (UK)	Tomohiro Arai (Japan & Belgium)
Eva Bosmans (Belgium)	Mark Evans (USA)	Tullio Ghi (Italy)
Eva Christin Weber (Germany)	Mark Kilby (UK)	Valentina De Robertis (Italy)
Fabio Peralta (Brazil)	Markus Gonser (Switzerland)	William Whitehead (USA)
Fatima Crispi (Spain)	Marta Rial Crestelo (Spain)	Wirada Dulyaphat (Thailand)
Federica Fontanella (Netherlands)	Megan Hall (UK)	Yoav Yinon (Israel)
Francesca Crovetto (Spain)	Melanie Nana (UK)	Yves Ville (France)
Francesca Russo (Belgium)	Michael Belfort (USA)	



New free-of-charge FMF software

This software can be downloaded from the FMF website. It allows:

- Recording of demographic characteristics and medical history.
- Recording of ultrasound findings at 11-14 weeks and calculation of risks for [major trisomies](#) in singleton and twin pregnancies based on a combination of maternal age, fetal NT, serum β -hCG and PAPP-A, fetal heart rate, nasal bone, tricuspid flow, ductus venosus flow and presence of major fetal defects.
- Assessment of risk for [preeclampsia](#) at 11-14, 19-24, 30-34 and 35-37 weeks' gestation. The risk is derived from a combination of demographic characteristics and elements of medical history in combination with mean arterial pressure, uterine artery pulsatility index, ophthalmic artery peak systolic velocity ratio, serum PIGF, sFLT-1, and glycosylated fibronectin.
- Assessment of [fetal growth and wellbeing](#) in singleton and twin pregnancies. This includes graphical presentation of fetal head circumference, abdominal circumference, femur length, estimated fetal weight, and Doppler indices of umbilical artery pulsatility index, middle cerebral artery pulsatility index and cerebroplacental ratio.